167 related articles for article (PubMed ID: 29205852)
1. Glycyrrhetinic Acid Functionalized Graphene Oxide for Mitochondria Targeting and Cancer Treatment In Vivo.
Zhang C; Liu Z; Zheng Y; Geng Y; Han C; Shi Y; Sun H; Zhang C; Chen Y; Zhang L; Guo Q; Yang L; Zhou X; Kong L
Small; 2018 Jan; 14(4):. PubMed ID: 29205852
[TBL] [Abstract][Full Text] [Related]
2. Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect.
Han C; Zhang C; Ma T; Zhang C; Luo J; Xu X; Zhao H; Chen Y; Kong L
Acta Biomater; 2018 Sep; 77():268-281. PubMed ID: 30006311
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
Qu Y; Sun F; He F; Yu C; Lv J; Zhang Q; Liang D; Yu C; Wang J; Zhang X; Xu A; Wu J
Eur J Pharm Sci; 2019 Nov; 139():105036. PubMed ID: 31446078
[TBL] [Abstract][Full Text] [Related]
4. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
Wang FZ; Xing L; Tang ZH; Lu JJ; Cui PF; Qiao JB; Jiang L; Jiang HL; Zong L
Mol Pharm; 2016 Apr; 13(4):1298-307. PubMed ID: 26894988
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
6. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
7. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
Du H; Liu M; Yu A; Ji J; Zhai G
Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
9. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
Wang X; Gu X; Wang H; Yang J; Mao S
Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
11. Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier.
Zhou T; Zhou X; Xing D
Biomaterials; 2014 Apr; 35(13):4185-94. PubMed ID: 24513318
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Zhang L; Yao J; Zhou J; Wang T; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
[TBL] [Abstract][Full Text] [Related]
13. Improved anti-tumor activity and safety profile of a paclitaxel-loaded glycyrrhetinic acid-graft-hyaluronic acid conjugate as a synergistically targeted drug delivery system.
Zhang L; Zhou JP; Yao J
Chin J Nat Med; 2015 Dec; 13(12):915-24. PubMed ID: 26721710
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
15. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid.
Tian Q; Wang XH; Wang W; Zhang CN; Wang P; Yuan Z
Nanomedicine; 2012 Aug; 8(6):870-9. PubMed ID: 22100756
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
17. Acid-sensitive polymeric vector targeting to hepatocarcinoma cells via glycyrrhetinic acid receptor-mediated endocytosis.
Yan T; Cheng J; Liu Z; Cheng F; Wei X; Huang Y; He J
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():32-40. PubMed ID: 29549947
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
[TBL] [Abstract][Full Text] [Related]
19. Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery.
Hefnawy A; Khalil IH; Arafa K; Emara M; El-Sherbiny IM
Int J Nanomedicine; 2020; 15():821-837. PubMed ID: 32103939
[TBL] [Abstract][Full Text] [Related]
20. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
